Brianna Abbott on Muck Rack

Brianna Abbott

Verified
Boston
As seen in: Techfluential by Deloitte, Folha de S.Paulo, MSN, MSN Canada, The New York Times, The New York Times en Español, Nature, The Wall Street Journal, The Wall Street Journal (China), The Wall Street Journal (Japan), Yahoo Finance and
Health reporter based in Boston. Previously at @WSJ covering the treatment and prevention of disease, with a focus on cancer t#SHERP36 PC’17

Get in touch with Brianna

Contact Brianna, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Putting the Patient at the Center of Care

|
By Brianna Abbott Verified
| Cancer Today Verified
JILL FELDMAN WAS CURLED UP on the bathroom floor in her home in Deerfield, Illinois, in 2019, her stomach aching with pain. Her 21-year-old son, Jack, discovered her and wanted to call 911, but Feldman insisted she was fine. Feldman, who was first diagnosed in 2009 with stage I non-small cell lung cancer that later metastasized, was accustomed to waiting out cancer treatment side effects. To stop Jack from calling emergency services, Feldman pushed herself up from the floor.
Open in Who Shared Issue with article?

ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come

|
By Brianna Abbott Verified
| BioSpace Verified
Pfizer arrived in Chicago this weekend for the American Society of Clinical Oncology’s annual conference fresh off a $10.5 billion deal with China’s Innovent Biologics, as the company seeks to bolster its oncology pipeline. “It is not a big [ASCO] year from the vantage-point of stock-moving data,” Leerink Partners analyst David Risinger told BioSpace.
Open in Who Shared Issue with article?

ASCO: A battle of bispecifics, Eli Lilly’s big win and more

|
By Brianna Abbott Verified
| BioSpace Verified
The American Society of Clinical Oncology (ASCO) conference was in full swing in Chicago this weekend, with researchers from around the world showcasing paradigm-shifting results and the next generation of cancer therapeutics. Revolution Medicines’ groundbreaking pancreatic cancer candidate daraxonrasib and Chinese biopharma Akeso and partner Summit Therapeutics’ PD-1/VEGF inhibitor ivonescimab grabbed the most attention.
Open in Who Shared Issue with article?
See all 608 licensed articles (660 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified